MorphoSys to Host Q3 2009 Conference Call on October 28, 2009
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publishits first nine months' 2009 results on October 28, 2009 at 7:00 a.m.CET.At 2:00 p.m. CET (1:00 p.m. GMT, 8:00 a.m. EDT), the Management Boardof MorphoSys AG will host a public conference call to presentMorphoSys's financial results for the first nine months of 2009 andprovide further details on the Company's latest developments.Dial-in numbers (listen only):Germany: +49 (0) 69 7104 8870United Kingdom: +44 (0) 1212 60 48 61USA: +1 (1) 866 268 19 47An audio replay and manuscripts of the conference will be availableon www.morphosys.com/conferencecalls in the afternoon of the sameday.About MorphoSys:MorphoSys is an independent biotechnology company that develops novelantibodies for therapeutic, diagnostic and research applications. TheCompany's HuCAL technology is one of the most powerful methodsavailable for generating fully human antibodies. By successfullyapplying this and other proprietary technologies, MorphoSys hasbecome a leader in the field of therapeutic antibodies, one of thefastest-growing drug classes in human health-care. Through itsalliances with some of the world's leading pharmaceutical companies,MorphoSys has created a pipeline of more than 60 drug candidates. TheCompany is expanding its drug pipeline by adding new partneredprograms, and by building a portfolio of fully-owned therapeuticantibodies. For its proprietary portfolio, the Company is focused onthe areas of oncology and inflammation, within which it plans to haveeight active programs by the end of 2009. Its most advanced programis MOR103, a first-in-class, fully human antibody against GM-CSF.MorphoSys expects to commence a Phase Ib/IIa trial of this antibodyin rheumatoid arthritis patients in the second half of 2009. Via itsbusiness unit AbD Serotec, MorphoSys is expanding the reach of itstechnologies in the diagnostics and research markets. MorphoSys isheadquartered in Munich, Germany and listed on the Frankfurt StockExchange under the symbol "MOR". For further information, visithttp://www.morphosys.com/HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® areregistered trademarks of MorphoSys AG.This communication contains certain forward-looking statementsconcerning the MorphoSys group of companies. The forward-lookingstatements contained herein represent the judgment of MorphoSys as ofthe date of this release and involve risks and uncertainties. Shouldactual conditions differ from the Company's assumptions, actualresults and actions may differ from those anticipated. MorphoSys doesnot intend to update any of these forward-looking statements as faras the wording of the relevant press release is concerned.For more information, please contact MorphoSys:Dr. Claudia Gutjahr-LöserHead of Corporate Communications & IRTel: +49 (0) 89 / 899 27-122gutjahr-loeser(at)morphosys.comMario BrkuljSenior Manager Corporate Communications & IRTel: +49 (0) 89 / 899 27-454brkulj(at)morphosys.comJessica KulpiSpecialist Corporate Communications & IRTel: +49 (0) 89 / 899 27-454kulpi(at)morphosys.comhttp://hugin.info/130295/R/1349504/325224.pdf --- End of Message ---MorphoSys AGLena-Christ-Str. 48 Martinsried / München GermanyWKN: 663200; ISIN: DE0006632003; Index: CDAX, HDAX, Prime All Share, TECH All Share, TecDAX, MIDCAP;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 22.10.2009 - 14:30 Uhr
Sprache: Deutsch
News-ID 7287
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 276 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys to Host Q3 2009 Conference Call on October 28, 2009"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
